New data for larotrectinib show overall response rates of 94% in children and 76% in adults with TRK fusion cancer; clinical benefit demonstrated in patients with primary central nervous system tumors and brain metastases (for specialized target groups only)

In children with TRK fusion cancer (n=34), the overall response rate (ORR) was 94% and durable, with median duration of response (DOR) not reached / In adults with TRK fusion cancer (n=74), the ORR was 76% and durable, with median DOR not reached / In evaluable patients with brain metastases (n=5), ORR was 60% / Improvements in quality of life were shown with larotrectinib treatment in both children and adults / Majority of adverse events were grade 1 or 2, as reported in prior publications
Source: Bayer Company News - Category: Pharmaceuticals Source Type: news